Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

ProQR Therapeutics N.V (PRQR) EBITDA: 2021-2025

Historic EBITDA for ProQR Therapeutics N.V (PRQR) over the last 5 years, with Sep 2025 value amounting to -$12.9 million.

  • ProQR Therapeutics N.V's EBITDA fell 38.37% to -$12.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$48.4 million, marking a year-over-year decrease of 85.17%. This contributed to the annual value of -$29.6 million for FY2024, which is 6.72% up from last year.
  • As of Q3 2025, ProQR Therapeutics N.V's EBITDA stood at -$12.9 million, which was up 11.43% from -$14.6 million recorded in Q2 2025.
  • ProQR Therapeutics N.V's EBITDA's 5-year high stood at -$2.8 million during Q2 2024, with a 5-year trough of -$22.9 million in Q3 2022.
  • For the 3-year period, ProQR Therapeutics N.V's EBITDA averaged around -$9.0 million, with its median value being -$9.3 million (2024).
  • In the last 5 years, ProQR Therapeutics N.V's EBITDA skyrocketed by 72.62% in 2023 and then plummeted by 418.55% in 2025.
  • Quarterly analysis of 5 years shows ProQR Therapeutics N.V's EBITDA stood at -$20.7 million in 2021, then skyrocketed by 34.40% to -$13.6 million in 2022, then surged by 56.56% to -$5.9 million in 2023, then tumbled by 68.70% to -$9.9 million in 2024, then tumbled by 38.37% to -$12.9 million in 2025.
  • Its EBITDA was -$12.9 million in Q3 2025, compared to -$14.6 million in Q2 2025 and -$11.0 million in Q1 2025.